TBK1 inhibitors as novel therapeutics for rheumatoid arthritis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1055374

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

A key feature of rheumatoid arthritis is inflammation in affected joints causing pain and immobility. New drugs that selectively block processes that are dysregulated in rheumatoid arthritis are needed to better treat this disease. The protein called TBK1 is a key regulator of inflammation and we aim to develop drugs that inhibit TBK1 activity thereby blocking the inflammation and symptoms associated with rheumatoid arthritis.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2016

Funding Scheme: Development Grants

Funding Amount: $511,722.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medicinal and Biomolecular Chemistry not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

autoimmune disease | drug development | inflammatory arthritis | medicinal chemistry | rheumatoid arthritis

Related Links